Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 33,180 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Neoplasm Malignant
Interventions: SAR302503 (TG101348), Placebo SAR302503, Panolosetron; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: Los Angeles, California • Augusta, Georgia • Detroit, Michigan + 4 more

Conditions: Clinical Pharmacology, Healthy Volunteer Study
Interventions: Placebo, Pomalidomide, Moxifloxacin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Ocular Surface Disease
Interventions: Fishoil supplement, Olive Oil; Dietary Supplement
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
Interventions: Dexamethasone Early, Dexamethasone Late; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 13 Days to 15 Days
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1994
U.S. locations: 13
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more

Conditions: Opioid-induced Constipation
Interventions: Methylnaltrexone bromide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Vasodilation, Blood Pressure, Active Hyperemia, Aging
Interventions: Super Beets, Beetroot powder; Dietary Supplement
Lead sponsor: University of Iowa; Other
Eligibility: 60 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Relapsing Remitting MS, Secondary Progressive MS, Primary Progressive MS
Interventions: Caprylic Triglyceride, Placebo; Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 59 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Smoking
Interventions: bupropion, placebo; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Postmenopausal Symptoms
Interventions: Estrogel, Placebo; Drug · Other
Lead sponsor: ASCEND Therapeutics; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 109
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more

Conditions: Healthy Volunteers
Interventions: TR-701 FA with Tyramine, Placebo-controlled withTyramine; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Alzheimer's Disease
Interventions: bapineuzumab, placebo; Drug · Other
Lead sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 26
States / cities: Sun City, Arizona • Irvine, California • Los Alamitos, California + 23 more

Conditions: Tinnitus
Interventions: Neuromonics Tinnitus Treatment Program, Placebo Device; Device
Lead sponsor: United States Army Aeromedical Research Laboratory; Federal
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Fort Rucker, Alabama

Conditions: Hyperlipidemia
Interventions: FishOil, CBE75, CBE150, placebo; Dietary Supplement
Lead sponsor: MetaProteomics LLC; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Gig Harbor, Washington

Conditions: Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
Interventions: Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, Ethanol Infusion, PTSD Reactivity Condition, Alcohol Cue Reactivity; Drug · Procedure · Behavioral
Lead sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance; Other
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: ADHD Specifically With Executive Function Impairment
Interventions: SPD489, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 39
States / cities: Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 34 more

Conditions: Mucopolysaccharidosis II
Interventions: iduronate-2-sulfatase enzyme replacement therapy, Placebo; Biological
Lead sponsor: Shire; Industry
Eligibility: 5 Years to 25 Years · Male only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 4
States / cities: Oakland, California • St Louis, Missouri • Chapel Hill, North Carolina + 1 more

Conditions: Juvenile Idiopathic Arthritis
Interventions: SLEEPSAMRT; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 8 Years to 13 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 1 Diabetes, Heart Disease
Interventions: Vitamin E, Dummy pills; Dietary Supplement · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 30 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type I Hypersensitivity
Interventions: Grass MATA MPL, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 1,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 65
States / cities: Colorado Springs, Colorado • Denver, Colorado • Englewood, Colorado + 58 more

Conditions: Anxiety, Pain, Distress, Emotional
Interventions: Electrical heating pad, Sham heating pad; Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Peripheral Vascular Diseases
Interventions: G-CSF, Placebo, Aspirin, Clopidogrel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Aging
Interventions: Placebo, Nutritional Supplement, In-home exercise, Testosterone; Drug · Dietary Supplement · Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 65 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Galveston, Texas

Conditions: Healthy Volunteers
Interventions: oxybutynin chloride immediate-release, oxybutynin chloride topical gel, placebo; Drug · Other
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 60 Years to 79 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 6
States / cities: Tucson, Arizona • National City, California • Maitland, Florida + 3 more

Search by objective public record fields.

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

A Phase 1 QT Study in Healthy Male Subjects

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Omega 3 Supplementation and Ocular Surface Disease in Glaucoma

Dexamethasone Therapy in VLBW Infants at Risk of CLD

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

Nitrate Supplementation and Muscle Blood Flow

Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis

Bupropion for Hospital-Based Smoking Cessation

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

Treating Tinnitus Using the Neuromonics Tinnitus Treatment Program: A Randomized, Double-blind Study

Effect of Citrus Bioflavonoids/Vitamin E in Conjunction With Fish Oil Supplementation

Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)

Sleep Shared-Management Intervention for Children With Juvenile Idiopathic Arthritis

Haptoglobin Phenotype, Vitamin E and High-density Lipoprotein (HDL) Function in Type 1 Diabetes

Efficacy and Safety/Tolerability of Grass MATA MPL

Heating Pad for in Office Cystoscopy and Urodynamic Testing

Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease

Feasibility Study of Post-hospitalization Interventions to Improve Physical Function in Older Adults

Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers